HEREFORD, PA — 20/15 Visioneers and Sravathi AI have announced a strategic partnership to introduce Sravathi AI’s advanced drug discovery platform to the North American market. This collaboration aims to revolutionize the drug discovery process by leveraging cutting-edge artificial intelligence technologies, offering new opportunities for biopharma and biotech industries.
Sravathi AI’s platform is at the forefront of innovation, using proprietary AI-driven methods to enhance drug design and discovery. The platform employs deep learning generative AI, computational chemistry, and molecular modeling to streamline the identification and optimization of small molecule assets. This technology allows for the rapid selection of promising compounds, significantly reducing the time and cost associated with drug development.
The platform’s capabilities include in-silico drug discovery, with features such as property prediction, advanced molecular dynamics methods, and hit-to-lead optimization. In addition, its in-silico chemistry tools offer predictions for synthesis routes, impurities, toxicity, and yield, providing a comprehensive solution for drug discovery and development.
Dr. Kishan Gurram, Founder and Managing Director of Sravathi AI, expressed enthusiasm about the partnership, stating, “We are excited to partner with 20/15 Visioneers to offer our drug discovery and Chemistry AI solutions to a broad set of Biopharma and Biotech clients. By combining our artificial intelligence platforms with their marketing expertise, we hope to create novel therapeutics for a broad set of Biopharma, Biotech and Chemistry clients that are more effective, safer and faster to develop.”
This partnership is set to make a significant impact in the pharmaceutical industry by enhancing the efficiency and success rate of drug discovery, ultimately leading to the development of more effective and safer therapeutics.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.